US Stock MarketDetailed Quotes

SMMT Summit Therapeutics

Watchlist
  • 17.870
  • -0.530-2.88%
Close Dec 20 16:00 ET
  • 17.990
  • +0.120+0.67%
Post 20:01 ET
13.18BMarket Cap-77.70P/E (TTM)

Summit Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Summit Therapeutics Q3 2024 Earnings Date

Currency：USDOct 30, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
0
0
0
--
--
--
EPS
--
-0.08
--
-166.67%
Analyst Rating
Strong Buy

Dec 11, 2024

Summit Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: GBP

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Oct 30, 20242024/Q30.000 / 0.000--
Aug 6, 20242024/Q20.000 / 0.000--
May 1, 20242024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Oct 30, 20242024/Q30.000 / 0.000--
Aug 6, 20242024/Q20.000 / 0.000--
May 1, 20242024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Summit Therapeutics Earnings Reports

  • Summit Therapeutics | 10-Q: Q3 2024 Earnings Report

    Oct 30 07:36 ET

  • Summit Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 6 07:43 ET

  • Summit Therapeutics | 8-K: Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024

    Aug 6 07:19 ET

  • Summit Therapeutics | 8-K: Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

    May 1 08:24 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Dec 11, 2024

    Strong Buy

    • Buy

      83.33%

    • Hold

      16.67%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Price
    % Chg

    No Data